Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

New scanning method detects basal cell carcinoma early using AI (opens in a new tab)

news-medical.net · 2026-09-22

Short answerEvidenceSource

Short answer

Not supported

Not supported.

2 claims go further than the study. 3 other points were not covered by the paper.

  • 2 overstated
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Not supported

Two of five claims overstate the study. Three claims the study doesn't address.

  • 2 overstated
  • 3 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedIn a feasibility study, the team systematically screened the faces of patients at high risk of developing skin cancer and, for the first time, detected basal cell carcinoma before any visible skin changes developed.View evidenceHide evidence

As statedfor the first time

Why this verdict

The paper supports a prospective cross-sectional feasibility study that systematically screened inconspicuous facial skin in high-risk inpatients and detected histologically confirmed subclinical BCCs. But the story’s “for the first time” novelty claim is not supported in the abstract profile, and “before any visible skin changes developed” is stronger than the paper’s described scope of inconspicuous skin after excluding macroscopically suggestive lesions.

1

Study evidence

AI-assisted LC-OCT identified 18 lesions as BCC; 15 of these were histologically confirmed, giving a PPV of 83.3% (95% CI, 58.1%–96.4%).PPV 83.3% (95% CI, 58.1%–96.4%)

“This prospective cross-sectional feasibility study was conducted from April 2025 to October 2025”
Claim 2 of 5OverstatedThe story suggests broader future use could allow earlier diagnosis and potentially more widespread cream-based treatment, possibly avoiding surgery in some cases.View evidenceHide evidence

Why this verdict

The paper profile supports the premise that subclinical BCC detection might enable earlier diagnosis, and the introduction notes that early diagnosis can permit less invasive treatment. But the profile does not provide evidence that broader use would increase cream-based treatment or avoid surgery; it explicitly notes that further studies are needed to determine whether earlier detection confers clinical benefit. Even though the story hedges this as future potential, it goes beyond the evidence in this feasibility diagnostic study.

1

Study evidence

AI-assisted LC-OCT identified 18 lesions as BCC; 15 of these were histologically confirmed, giving a PPV of 83.3% (95% CI, 58.1%–96.4%).PPV 83.3% (95% CI, 58.1%–96.4%)

“This prospective cross-sectional feasibility study was conducted from April 2025 to October 2025”
Claim 3 of 5Not coveredResearchers at FAU combined an optical diagnosis method with AI-assisted image recognition in a new approach called SUBSCAN.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that the study used AI-assisted LC-OCT, an optical imaging method, for screening inconspicuous facial skin in high-risk patients. However, the supplied paper profile does not verify the FAU framing or the name “SUBSCAN,” so the full headline-style claim is only partly checkable at this depth.

1

Study evidence

AI-assisted LC-OCT identified 18 lesions as BCC; 15 of these were histologically confirmed, giving a PPV of 83.3% (95% CI, 58.1%–96.4%).PPV 83.3% (95% CI, 58.1%–96.4%)

“This prospective cross-sectional feasibility study was conducted from April 2025 to October 2025”
Claim 4 of 5Not coveredThe AI reportedly provides a real-time color-coded probability value for basal cell carcinoma, but the physician still makes the final diagnosis.View evidenceHide evidence

Why this verdict

The abstract-level paper profile supports AI-assisted LC-OCT with automated lesion classification, but it does not describe a real-time color-coded probability display or specify that the physician makes the final diagnosis. Those workflow/interface details are not verifiable from the supplied abstract profile.

1

Study evidence

AI-assisted LC-OCT identified 18 lesions as BCC; 15 of these were histologically confirmed, giving a PPV of 83.3% (95% CI, 58.1%–96.4%).PPV 83.3% (95% CI, 58.1%–96.4%)

“This prospective cross-sectional feasibility study was conducted from April 2025 to October 2025”
Claim 5 of 5Not coveredThe article says the approach is not yet ready for routine use because there is still a lack of sensitivity data and the method is too time-consuming.View evidenceHide evidence

Why this verdict

The paper profile supports caution against routine implementation and specifically notes the need for further prospective studies to assess sensitivity, cost-effectiveness, and clinical benefit. However, the stated reason that the method is “too time-consuming” is not present in the supplied abstract-level profile, so the full causal explanation is not fully verifiable at this depth.

1

Study evidence

AI-assisted LC-OCT identified 18 lesions as BCC; 15 of these were histologically confirmed, giving a PPV of 83.3% (95% CI, 58.1%–96.4%).PPV 83.3% (95% CI, 58.1%–96.4%)

“This prospective cross-sectional feasibility study was conducted from April 2025 to October 2025”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Histologic confirmation was the primary reference standard for AI-positive lesions, with two AI-positive lesions not biopsied

    The story summary does not mention the histology reference standard, the 15-of-18 primary confirmation result, or the two nonbiopsied AI-positive lesions. This matters because the diagnostic-performance evidence is based on partial verification.

    From Prospective cross-sectional feasibility study; Sensitivity analysis with alternative verification (expert image adjudica

  • Positive predictive value estimates and uncertainty: 83.3% PPV in primary analysis, 94.4% in sensitivity analysis with expert confirmation

    The story describes the screening approach and caveats but does not convey the central quantitative performance estimates or their wide confidence intervals.

    From Prospective cross-sectional feasibility study; Sensitivity analysis with alternative verification (expert image adjudica

  • Detected subclinical BCCs: 17 lesions in 14 of 150 patients

    The story states that subclinical BCC was detected but does not report the study’s detection counts or patient denominator, which are important for gauging the scale of evidence.

    From Prospective cross-sectional feasibility study

  • Single-center inpatient population with at least two BCC risk factors limits generalizability

    The story notes high-risk patients but does not mention the single-center inpatient setting or the ≥2-risk-factor inclusion criterion, which limit generalization to broader screening populations.

    From Prospective cross-sectional feasibility study; Prospective cross-sectional feasibility study

  • Small number of confirmed BCC cases and wide confidence intervals limit precision

    The story’s caveats do not include the small lesion counts or imprecision of the diagnostic and subtype estimates, an important limitation for interpreting feasibility-study results.

    From Prospective cross-sectional feasibility study; Prospective cross-sectional feasibility study; Sensitivity analysis with

  • Subtype classification accuracy was a secondary endpoint

    The paper profile includes subtype distribution and AI-LC-OCT subtype match with histology, but the story presentation does not discuss this secondary diagnostic-classification result.

    From Prospective cross-sectional feasibility study

4 things the story did carry across
  • Prospective cross-sectional feasibility design in high-risk inpatients
  • Systematic screening was of inconspicuous facial skin after excluding macroscopically suggestive lesions
  • Primary diagnostic performance endpoint was PPV, not sensitivity
  • Need for further studies before routine implementation, including sensitivity, cost-effectiveness, and clinical benefit
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoAssess feasibility and diagnostic performance (PPV) of systematic screening of inconspicuous facial skin in high-risk patients using AI-assisted LC-OCT to detect subclinical basal cell carcinoma, with histology as reference.Prospective cross-sectional feasibility studyExpand

In plain English

Prospective cross-sectional feasibility study evaluating systematic screening of inconspicuous facial skin with AI-assisted line-field confocal optical coherence tomography (LC-OCT) in consecutive inpatients at high risk for basal cell carcinoma (≥2 risk factors). The prespecified primary outcome was positive predictive value (PPV) of AI-assisted LC-OCT for histologically confirmed subclinical BCC; histologic confirmation was obtained for AI-positive lesions when biopsied.

Key findings

  • AI-assisted LC-OCT identified 18 lesions as BCC; 15 of these were histologically confirmed, giving a PPV of 83.3% (95% CI, 58.1%–96.4%).PPV 83.3% (95% CI, 58.1%–96.4%)
  • Sensitivity analysis that included the 2 nonbiopsied lesions as confirmed by expert analysis yielded a PPV of 94.4% (95% CI, 72.7%–99.9%).PPV 94.4% (95% CI, 72.7%–99.9%)
“This prospective cross-sectional feasibility study was conducted from April 2025 to October 2025”
What this piece can’t prove
  • Two AI-positive lesions were not biopsied because patients declined, resulting in incomplete reference-standard verification for those cases.
  • Feasibility cross-sectional design and single-center recruitment of inpatients with ≥2 BCC risk factors limit ability to estimate sensitivity, specify screening yield in broader populations, or determine clinical benefit of earlier detection.
  • Relatively small number of confirmed BCC cases and lesions for subtype-accuracy estimates, resulting in wide confidence intervals.
  • Macroscopically suggestive lesions were excluded from screening, so findings apply to detection of inconspicuous (subclinical) facial lesions rather than general diagnostic use including obvious lesions.
2human in vivoEvaluate accuracy of AI-assisted LC-OCT in classifying BCC subtype (eg, superficial vs nodular vs infiltrative) compared with histology among detected subclinical BCCs.Prospective cross-sectional feasibility studyExpand

In plain English

In a prospective cross-sectional feasibility study of AI-assisted LC-OCT screening of inconspicuous facial skin in high-risk inpatients, 17 subclinical BCCs were detected; subtype distribution was 13 superficial (76.5%), 3 nodular (17.6%), and 1 infiltrative (5.9%). Among the 15 histologically confirmed subclinical BCCs, AI-assigned subtype matched histology in 13 cases (86.7%; 95% CI, 59.5%–98.3%).

Key findings

  • AI-assisted LC-OCT subtype assignment matched histologic subtype in 13 of 15 histologically confirmed subclinical BCCs.86.7% (13/15); 95% CI, 59.5%–98.3%
  • Distribution of BCC subtypes among detected subclinical BCCs was 13 superficial, 3 nodular, and 1 infiltrative.13/17 (76.5%) superficial; 3/17 (17.6%) nodular; 1/17 (5.9%) infiltrative
“The distribution of BCC subtypes included 13 cases of superficial BCCs (76.5%), followed by 3 cases of nodular BCCs (17.6%), and 1 case of infiltrative BCC (5.9%).”
What this piece can’t prove
  • Small sample size and small numbers of lesions in some subtype categories, yielding wide confidence intervals.
  • Two lesions diagnosed by AI did not undergo histologic confirmation and were excluded from the histology-based accuracy calculation.
  • Single-center, inpatient population of patients with ≥2 BCC risk factors; findings may not generalize to broader or community screening populations.
  • Cross-sectional feasibility design; study does not provide sensitivity estimates for screening or evidence of clinical benefit from earlier detection.
3human in vivoExplore impact of handling nonbiopsied AI-positive lesions via a sensitivity analysis (including expert confirmation) on PPV estimates.Sensitivity analysis with alternative verification (expert image adjudication)Expand

In plain English

Sensitivity analysis evaluated how treating two AI-positive, nonbiopsied facial lesions (patients declined biopsy) as true positives based on expert LC-OCT image review affects the estimated positive predictive value (PPV) for AI-assisted LC-OCT detection of subclinical BCC. Under this alternative verification, PPV was 94.4% (95% CI, 72.7%–99.9%), compared with the primary analysis PPV of 83.3% (95% CI, 58.1%–96.4%) based on histology.

Key findings

  • Including two AI-positive lesions that were not biopsied but were confirmed by expert LC-OCT image review increased the PPV of AI-assisted LC-OCT for subclinical BCC to 94.4% (95% CI, 72.7%–99.9%).PPV 94.4% (95% CI, 72.7%–99.9%)
“2 patients declined biopsy.”
What this piece can’t prove
  • Two AI-positive lesions lacked histologic confirmation because patients declined biopsy; sensitivity analysis instead used expert image confirmation.
  • The sensitivity analysis result is based on a small number of additional cases, resulting in wide confidence intervals.
  • Expert LC-OCT confirmation is an alternative verification method and not equivalent to the histologic gold standard reported in the primary analysis.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 31 candidate papers

And 25 more candidates considered.